Novartis To Maintain Sales Force In Face Of Potential Competitor Cutbacks
Executive Summary
Novartis' decision to maintain its current sales force level could reflect the company's confidence in the continued growth of its pharmaceutical business
You may also be interested in...
Quality Not Quantity: Pfizer Cuts Sales Team To Increase Meaningful Contacts
Pfizer's decision to reduce its sales force reflects a change in the company's marketing strategy, but does not mean the firm is facing a shortage of products to support, according to CEO Jeffrey Kindler
Quality Not Quantity: Pfizer Cuts Sales Team To Increase Meaningful Contacts
Pfizer's decision to reduce its sales force reflects a change in the company's marketing strategy, but does not mean the firm is facing a shortage of products to support, according to CEO Jeffrey Kindler
Elidel, Protopic Get Boxed Warnings On Cancer, But Not At Top Of Labeling
Boxed warnings about potential cancer risks will appear in the warning sections for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus)